Mevo (Formerly Nexodata)
Healthcare platform that makes people's lives easier, from a digital prescription with an online purchase option to medication delivered at home.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
* | BRL40.0m | Early VC | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 238 % | 241 % | 280 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Mevo, formerly known as Nexodata, is a Brazilian health-tech company that provides a digital prescription platform. The company's main goal is to streamline the process of receiving and fulfilling medical prescriptions by eliminating the need for paper-based documents. The platform allows healthcare professionals to issue electronic prescriptions that are sent directly to the patient's mobile device.
Mevo has expanded its business model to include an online marketplace. This allows patients to not only receive their prescriptions digitally but also to purchase the prescribed medications and other health, hygiene, and beauty products directly through the platform. The company has also implemented a delivery service, with the capability of getting medicines to the patient's home in as little as 45 minutes. This integrated approach connects doctors, patients, and pharmacies in a single ecosystem. The company operates in the Brazilian healthcare market and its clients include healthcare providers, technology companies, and pharmacies.
Keywords: health-tech, e-prescription, digital pharmacy, medication delivery, online marketplace, healthcare platform, telemedicine, Brazil, B2B, B2C